- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about CRSP
Recent news which mentions CRSP
3 Gene Editing Stocks With Unprecedented Surge Potential
February 13, 2024
From InvestorPlace
From Motley Fool
3 Groundbreaking Healthcare Stocks to Buy for Robust Gains
February 11, 2024
From InvestorPlace
$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,300 Today
February 09, 2024
From Benzinga
3 Strong Buy Healthcare Stocks to Add to Your February Must-Watch List
February 09, 2024
From InvestorPlace
The 3 Most Undervalued Biotech Stocks to Buy in February 2024
February 08, 2024
From InvestorPlace
2 Healthcare Stocks to Buy Hand Over Fist in February
February 08, 2024
From Motley Fool
Cathie Wood Just Bought These 3 Biotech Stocks. Should You?
February 07, 2024
From Motley Fool
2 Cathie Wood Stocks I Plan on Buying for My Kids' Portfolios
February 05, 2024
From Motley Fool
Got $100? 2 Top Cathie Wood Stocks to Buy and Hold.
February 04, 2024
From Motley Fool
Top Stock Picks 2024: 3 Healthcare Stocks Leading Medical Advancements
February 01, 2024
From InvestorPlace
Jim Cramer Says It's 'Still Not Too Late' To Buy This Energy Stock
January 31, 2024
From Benzinga
History Says the S&P 500 May Climb in the Triple Digits During This Bull Market. 3 Top Growth Stocks to Buy Before it Does.
January 30, 2024
From Motley Fool
Is CRISPR Therapeutics a Buy in the New Bull Market?
January 30, 2024
From Motley Fool
Cathie Wood Goes Bargain Hunting: 3 Stocks She Bought Last Week
January 28, 2024
From Motley Fool
Biotech Stocks Are on Fire: Here Are the Top 3 Picks for January
January 25, 2024
From InvestorPlace
Where Will CRISPR Therapeutics Be in 5 Years?
January 24, 2024
From Motley Fool
1 Setback and 1 Opportunity for CRISPR Therapeutics Stock
January 23, 2024
From Motley Fool
From Benzinga
If You Invested $10,000 in Vertex Pharmaceuticals in 2018, This Is How Much You Would Have Today
January 22, 2024
From Motley Fool
Could CRISPR Therapeutics Stock Help You Become a Millionaire?
January 22, 2024
Tickers
CRSP
From Motley Fool
Could Editas Medicine Become the Next CRISPR Therapeutics?
January 21, 2024
From Motley Fool
Better Growth Stock: Intellia Therapeutics vs. CRISPR Therapeutics
January 21, 2024
From Motley Fool
3 High-Flying Stocks That Could Soar Even More in 2024
January 20, 2024
From Motley Fool
3 Under-the-Radar Tech Stocks With 250% Growth Potential by 2026
January 18, 2024
From InvestorPlace
Cathie Wood's Ark Invest Sells $8.04M Worth of DraftKings Shares
January 17, 2024
From Benzinga
Gene Therapy For Beta-Thalassemia: CRISPR Therapeutics/Vertex's Casgevy Secures FDA Nod Ahead of Schedule
January 17, 2024
From Benzinga
Cathie Wood's Ark Invest Liquidates $15.8M Worth Of ProShares Bitcoin Strategy ETF Units
January 16, 2024
From Benzinga
These 2 Stocks Carry a Lot of Risk, but Their Upside Is Huge
January 16, 2024
From Motley Fool
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.